Navigation Links
Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
Date:10/14/2008

Company's INS-20 Receives Regulatory Clearance to Begin Phase I Clinical Trial

RICHMOND, Va., Oct. 14 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, today announced that it has received approval from the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I clinical study for the Company's second follow-on biologic (FOB) product candidate, INS-20. Insmed's INS-20 is a pegylated recombinant form of human G-CSF, and an FOB of the FDA-approved product Neulasta(R), which had U.S. sales of approximately $2.4 billion in 2007.

Pre-clinical studies demonstrated that INS-20 and FDA-approved Neulasta(R) are comparable in both their pharmacological and toxicological profile. Detailed analytical characterisation also demonstrated that the products have a high degree of similarity. Data from these initial evaluations have been used, in part, to support the Phase I study, which will be initiated immediately. The Phase I study will be conducted in the United Kingdom and will compare the safety and establish the bioequivalence of INS-20 to Neulasta(R). Results from the trial are anticipated in 2009, and are expected to be used as part of a submission to the FDA to establish a protocol with the agency for a Phase III trial.

"We continue to be pleased by the progress we are making in the development of our FOB portfolio, utilizing our unique protein drug development capabilities and technical expertise," said Dr. Geoffrey Allan, President and CEO of Insmed. "Each development milestone we achieve is further evidence of our strong position as a leader in this evolving industry. We intend to use the data to be generated from the Phase I trial, in combination with the positive pre-clinical results previously garnered, as the basis for discussions with the FDA in an effort to establish a Phase III development path for INS-20."

The initiation of t
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
2. Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company
3. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
4. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
5. Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
6. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
7. Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy
8. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
9. Baxter Initiates Phase III Trial for the Treatment of Alzheimers Disease
10. S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
11. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... VIEW, California , 20 de octubre de ... líder en el campo de la pulmonología intervencional, ... su Estudio RENEW, casi 3 meses antes de ... fundamental de exención de dispositivo de investigación (IDE) ... Medicamentos) para el sistema de espiral de reducción ...
(Date:10/20/2014)... SAN DIEGO , Oct. 20, 2014   BioNano ... the Irys system: the ability to collect human data at ... on a single chip.  This new capability was established and ... for the Irys TM System and will ... next two months. BioNano will be showcasing this advancement at ...
(Date:10/20/2014)...   Mary,s Medicinals today announced that its ... Sponsor of Operation Grow4Vets , a national, nonpartisan ... and services to assist them in living with injuries ... , An ever-increasing number of medical studies ... treatment for pain, Post-traumatic Stress Disorder (PTSD) and Traumatic ...
Breaking Medicine Technology:PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 2Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 3
... 2011 Reportlinker.com announces that a new market research report ... In Vitro Diagnostics Market http://www.reportlinker.com/p0470752/World-In-Vitro-Diagnostics-Market.html ... through 2014 The Freedonia Group projects world ... annually to nearly $68 billion in 2014. Based on the ...
... Reportlinker.com announces that a new market research report ... European Markets for Patient Monitoring Devices and Equipment ... In 2010, the European patient monitoring ... 2008 and 2009. This mature market is expected ...
Cached Medicine Technology:Reportlinker Adds World In Vitro Diagnostics Market 2Reportlinker Adds World In Vitro Diagnostics Market 3Reportlinker Adds World In Vitro Diagnostics Market 4Reportlinker Adds World In Vitro Diagnostics Market 5Reportlinker Adds World In Vitro Diagnostics Market 6Reportlinker Adds World In Vitro Diagnostics Market 7Reportlinker Adds World In Vitro Diagnostics Market 8Reportlinker Adds World In Vitro Diagnostics Market 9Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 2Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 3Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 4Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 5Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 6Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 7Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 8Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 9Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 10Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 11Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 12Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 13Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 14Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 15Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 16Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 17Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 18Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 19Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 20Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 21
(Date:10/20/2014)... (PRWEB) October 20, 2014 Based ... are the only imaging assays capable of determining ... single test.  With these three dimensions of high-resolution ... to detect the widest range of disease-causing genetic ... missed by other genomic tools, including today’s advanced ...
(Date:10/20/2014)... 2014 Unveiled at the Sept. 18 board ... conservatively estimates member hospital ROI on membership dues at 12.5. ... Center provides $12.50 in value to member hospitals. The calculation ... Member Dues)/Member Dues. , “This is the first time ... we think the methodology is really sound,” said Bill ...
(Date:10/20/2014)... Houston, Texas (PRWEB) October 20, 2014 ... invited to present the key elements of his innovative ... visiting professor to plastic surgery residents and faculty at ... (UTMB) , where he, too, was once a medical ... of the largest private cosmetic plastic surgery practices in ...
(Date:10/19/2014)... October 20, 2014 The leading ... ( http://www.top10bestseohosting.com/go/iPage/ ) and GreenGeeks are the best ... platforms for those who want to buy high ... time. , The IT manager of Top10BestSEOHosting.com says, ... most recommended suppliers for everyone. A lot of ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 This ... for Partial Seizure, complete with comparative analysis at ... of action (MoA), route of administration (RoA) and ... news and press releases. It also reviews key ... Seizure and special features on late-stage and discontinued ...
Breaking Medicine News(10 mins):Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4
... simple diagnostic modality can help predict the outcome of ... It can predict which patient would benefit from the ... valuable study can be found in the latest issue ... physicians identify factors that cause specific symptoms by demonstrating ...
... prescription drugs in the filtered and recycled wastewater at ... dangerous effects this water might have in the future. ... antibiotics, antipsychotics, birth-control hormones, Viagra and Valium have been ... the wastewater is because people flush them down their ...
... Boston, a surgery was conducted on a baby inside the womb. ... the womb. // She was discharged on Friday after the successful ... a heart defect called hypoplastic left heart syndrome (HLHS) inside the ... in the developing fetus on November 7, 2005. ,She ...
... services in a hospital at Brisbane a patient had to ... was attacked and was in serious condition, attention could not ... Caboolture Hospital, where emergency services are scarce due to shortage ... presently operational from 8am to 6pm every day. ...
... announced that it intends to fast track its inhaled insulin ... Food and Drug Administration // and the European Commission ... Sanofi-Aventis and Nektar Therapeutics. ,It is a relatively ... or syringes are needed. "Until today, patients with diabetes who ...
... successfully reached the Vinson Massif summit, one of Antarctica's ... and was successfully completed on January 19th after eight ... was a strong, healthy athlete who was later diagnosed ... of the disease he lost 80 pounds and his ...
Cached Medicine News:Health News:SPECT Can Help Predict Treatment Outcome In Patients With Low Back Pain 2Health News:Medications Detected In Recycled Water In Los Angeles 2Health News:Baby Underwent A Heart Surgery Inside The Womb 2Health News:Crohn's Patient Robert Hill’s greatest achievemen 2
Toothed grasping forcep....
Bateman pituitary forceps, round cup, 5 mm bite, fenestrated crocodile jaws, 150 mm effective....
Micro cup pituitary forceps, semi-malleable shafts....
Bayonet Kerrison Rongeur, ceramic ejector, 9.5 length 40 Fwd, 6.5 working length 165 mm....
Medicine Products: